ViroGates is an international Medtech company headquartered North of Copenhagen, in the heart of Medicon Valley.

About ViroGates

ViroGates was founded in 2001 based on an invention from Hvidovre University Hospital, Denmark.

Inventor and co-founder Jesper Eugen-Olsen initially discovered the utility of the biomarker suPAR in HIV. More than 900 publications have followed, substantiating suPAR as one of the most promising prognostic biomarkers across diseases. ViroGates has developed a patented product line called suPARnostic® to make the suPAR test commercially available.

The suPAR biomarker predicts patient outcomes across diseases by measuring the activation level of the immune system. suPARnostic® is a fast and reliable prognostic biomarker that enables healthcare professionals to make quick and informed patient triaging decisions in emergency departments.

Implementing suPARnostic® in clinical care saves critical resources and valuable time and results in vastly reduced healthcare costs, more efficient triage, and better patient outcomes.

suPARnostic® delivers faster and safer patient discharges, reduces readmissions, avoids unnecessary admissions, and lowers hospital length of stay.

Seamlessly implemented by clinicians and laboratory technicians, suPARnostic® products fit existing workflows in hospitals, are approved for all the major clinical chemistry analyzers, and deliver results in less than 20 minutes.

How suPARnostic® works at the Emergency department

Step 1

A patient is admitted to the emergency department for observation

Step 2

The patient’s blood sample is drawn

Step 3

The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.

Step 4

The physician gets the result and makes a triage decision

“Wanted to share with you our latest study comparing suPAR assays. It places ViroGates suPARnostic® as the gold standard for measuring suPAR (1)”

– Dr. Salim Hayek, Medical Director, Michigan Medicine Frankel, Cardiovascular Center Clinics
Author of two New England Journal of Medicine papers about suPAR (2,3)

Our Vision and Mission

We envision a healthcare system where the suPAR biomarker makes a difference by providing information that empowers clinicians to save lives and provide patients with the treatment they need.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

Quick Triage
TurbiLatex
ELISA
POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates